Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients

International Clinical Psychopharmacology

Volumn 24, Issue 3, 2009, Pages 139-144

  Lee, Seung Tae ^a   Ryu, Seunghyong ^a   Nam, Hee Jung ^a   Lee, Soo Youn ^a   Hong, Kyung Sue ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Clozapine; Korean; Metabolic ratio; Norclozapine; Therapeutic response

Indexed keywords

CLOZAPINE; NORCLOZAPINE; DRUG DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; ASIAN; CAUCASIAN; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; HUMAN; KOREA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC RATE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEX RATIO; SMOKING HABIT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; AGING; BLOOD; DOSE RESPONSE; METABOLISM; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; REGRESSION ANALYSIS; SMOKING;

ADULT; AGING; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KOREA; MALE; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; TREATMENT OUTCOME;

EID: 67649239977     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283277627     Document Type: Article

References (30)

1. Ackenheil M, Brau H, Burkhart A, Franke A, Pacha W (1976). [Antipsychotic efficacy in relation to plasma levels of clozapine (author's transl)]. Arzneimittelforschung 26:1156-1158.
2. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al. (2004). The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37: 243-265.
3. Chong SA, Tan CH, Khoo YM, Lee HS, Wong KE, Ngui F, et al. (1997). Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit 19:219-223.
4. Chung C, Remington G (2005). Predictors and markers of clozapine response. Psychopharmacology (Berl) 179:317-335.
5. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL (2005). The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl) 178: 178::451-460.
6. Desai HD, Seabolt J, Jann MW (2001). Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 15:469-494.
7. Diaz FJ, de Leon J, Josiassen RC, Cooper TB, Simpson GM (2005). Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res 72:131-135.
8. Frazier JA, Cohen LG, Jacobsen L, Grothe D, Flood J, Baldessarini RJ, et al. (2003). Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol 23: 87-91.
9. Goldman M, DeQuardo JR, Tandon R, Taylor SF, Jibson M (1999). Symptom correlates of global measures of severity in schizophrenia. Compr Psychiatry 40:458-461.
10. Greenwood-Smith C, Lubman DI, Castle DJ (2003). Serum clozapine levels: a review of their clinical utility. J Psychopharmacol 17:234-238.
11. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A (1990). Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 147:1471-1475.
12. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H (1989). Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl) 99 (Suppl): S38-S40.
13. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. (2003). The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 416 (Suppl):16-23.
14. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY (1993). Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 13:383-390.
15. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM (2003). Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 15:33-48.
16. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
17. Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW (2007). Pharmacology of N-desmethylclozapine. Pharmacol Ther 115: 223-231.
18. Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY (2005). N- desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 30:1986-1995.
19. Liu HC, Chang WH, Wei FC, Lin SK, Lin SK, Jann MW (1996). Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 18:200-207.
20. Matsuda KT, Cho MC, Lin KM, Smith MW, Young AS, Adams JA (1996). Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 32:253-257.
21. Mauri MC, Volonteri LS, Dell'Osso B, Regispani F, Papa P, Baldi M, et al. (2003). Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 23:660-664.
22. Meltzer HY (1997). Treatment-resistant schizophrenia - the role of clozapine. Curr Med Res Opin 14:1-20.
23. Ng CH, Chong SA, Lambert T, Fan A, Hackett LP, Mahendran R, et al. (2005). An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 20:163-168.
24. Olesen OV (1998). Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. Clin Pharmacokinet 34:497-502.
25. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 24:70-78.
26. Tang YL, Mao P, Li FM, Li W, Chen Q, Jiang F, et al. (2007). Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol 64:49-56.
27. Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B, et al. (2003). Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 41:3-13.
28. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB (1996). Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153:1579-1584.
29. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, et al. (2004). The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 177:207-216.
30. Young CR, Bowers MB Jr, Mazure CM (1998). Management of the adverse effects of clozapine. Schizophr Bull 24:381-390.